Physician profile
Arjun Nair
NPI 1982866968
$6,404.50
in general payments reported to CMS, 2019-2025
33 companies · $613 in 2025
The $613 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $653 · 2021: $1,146 · 2022: $1,548 · 2023: $1,011 · 2024: $693 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,317.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $787.33 | 2019-2025 | |
| Pfizer INC. | $758.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $690.62 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $606.90 | 2019-2025 | |
| Abbott Laboratories | $522.98 | 2019-2024 | Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit, Confirm Rx |
| E.R. Squibb & Sons, L.L.C. | $285.78 | 2019-2025 | Eliquis, Camzyos |
| Amgen INC. | $235.64 | 2019-2023 | Repatha |
| Novo Nordisk INC | $234.45 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Medtronic, INC. | $197.65 | 2022-2025 | Corevalve Evolut R |
| Amarin Pharma, INC. | $182.10 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $180.31 | 2021-2024 | Lifevest |
| Sanofi-Aventis U.S. LLC | $148.39 | 2019-2024 | |
| Ge Healthcare | $146.42 | 2022 | |
| Merck Sharp & Dohme LLC | $146.39 | 2021-2025 | Verquvo |
| Cleerly, INC. | $141.35 | 2024-2025 | Cleerly Labs, Cleerly Ischemia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $140.07 | 2019-2022 | |
| Astellas Pharma US INC | $128.34 | 2020 | |
| Esperion Therapeutics, INC. | $127.08 | 2021-2024 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $122.85 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.89 | 2020-2023 | Jardiance |
| Innovation Technologies INC | $86.90 | 2022-2023 | Irrisept |
| Angiodynamics, INC. | $76.19 | 2021-2022 | |
| Cvrx, INC. | $65.43 | 2022-2024 | Barostim Neo System |
| Regeneron Healthcare Solutions, INC. | $47.53 | 2019 | |
| Inspire Medical Systems, INC. | $46.11 | 2023-2024 | Inspire |
| Kiniksa Pharmaceuticals, LTD. | $37.54 | 2021-2023 | Arcalyst |
| Glaxosmithkline, LLC. | $34.28 | 2025 | Arexvy |
| Baxter Healthcare | $30.22 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $28.53 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.75 | 2025 | |
| Cashflow Solutions, LLC | $23.59 | 2023 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Gilead Sciences, INC. | $17.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.